Reach Us +32 25889658


SCAR2.0 Treating Refractory B Cell Lymphomas: An advanced Technology Saves More Lives!

CAR-T cell therapy represents an innovative and effective therapy for patients with refractory/relapsed B cell malignancies. However, many limitations remain with the currently approved CAR-T products, including antigen escape, CAR-T exhaustion in vivo, significant toxicity, and high cost, to name a few.


Cheng Jiao* and Lung-Ji Chang

Abstract | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

agar io

wormax io